410 related articles for article (PubMed ID: 32243841)
21. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.
Shi R; Radulovich N; Ng C; Liu N; Notsuda H; Cabanero M; Martins-Filho SN; Raghavan V; Li Q; Mer AS; Rosen JC; Li M; Wang YH; Tamblyn L; Pham NA; Haibe-Kains B; Liu G; Moghal N; Tsao MS
Clin Cancer Res; 2020 Mar; 26(5):1162-1174. PubMed ID: 31694835
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in organoid development and applications in disease modeling.
Rauth S; Karmakar S; Batra SK; Ponnusamy MP
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188527. PubMed ID: 33640383
[TBL] [Abstract][Full Text] [Related]
23. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
[TBL] [Abstract][Full Text] [Related]
24. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
[TBL] [Abstract][Full Text] [Related]
25. The Use of Stem Cell-Derived Organoids in Disease Modeling: An Update.
Azar J; Bahmad HF; Daher D; Moubarak MM; Hadadeh O; Monzer A; Al Bitar S; Jamal M; Al-Sayegh M; Abou-Kheir W
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299287
[TBL] [Abstract][Full Text] [Related]
26. Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism.
Bose S; Yao H; Huang Q; Whitaker R; Kontos CD; Previs RA; Shen X
J Ovarian Res; 2022 Oct; 15(1):114. PubMed ID: 36266675
[TBL] [Abstract][Full Text] [Related]
27. Medium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived Organoids.
Putker M; Millen R; Overmeer R; Driehuis E; Zandvliet MMJM; Clevers H; Boj SF; Li QX
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33999032
[TBL] [Abstract][Full Text] [Related]
28. Organoid culture systems for prostate epithelial and cancer tissue.
Drost J; Karthaus WR; Gao D; Driehuis E; Sawyers CL; Chen Y; Clevers H
Nat Protoc; 2016 Feb; 11(2):347-58. PubMed ID: 26797458
[TBL] [Abstract][Full Text] [Related]
29. Application of Ovarian Cancer Organoids in Precision Medicine: Key Challenges and Current Opportunities.
Yang J; Huang S; Cheng S; Jin Y; Zhang N; Wang Y
Front Cell Dev Biol; 2021; 9():701429. PubMed ID: 34409036
[TBL] [Abstract][Full Text] [Related]
30. An Organoid-Based Preclinical Model of Human Gastric Cancer.
Steele NG; Chakrabarti J; Wang J; Biesiada J; Holokai L; Chang J; Nowacki LM; Hawkins J; Mahe M; Sundaram N; Shroyer N; Medvedovic M; Helmrath M; Ahmad S; Zavros Y
Cell Mol Gastroenterol Hepatol; 2019; 7(1):161-184. PubMed ID: 30522949
[TBL] [Abstract][Full Text] [Related]
31. Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment.
Hu H; Sun C; Chen J; Li Z
J Cancer Res Clin Oncol; 2024 Mar; 150(3):146. PubMed ID: 38509422
[TBL] [Abstract][Full Text] [Related]
32. A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening.
Zhang L; Liu F; Weygant N; Zhang J; Hu P; Qin Z; Yang J; Cheng Q; Fan F; Zeng Y; Tang Y; Li Y; Tang A; He F; Peng J; Liao W; Hu Z; Li M; Liu Z
Cancer Lett; 2021 Mar; 500():87-97. PubMed ID: 33309780
[TBL] [Abstract][Full Text] [Related]
33. Current Status of Patient-Derived Ovarian Cancer Models.
Maru Y; Hippo Y
Cells; 2019 May; 8(5):. PubMed ID: 31130643
[TBL] [Abstract][Full Text] [Related]
34. Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture.
Elbadawy M; Usui T; Mori T; Tsunedomi R; Hazama S; Nabeta R; Uchide T; Fukushima R; Yoshida T; Shibutani M; Tanaka T; Masuda S; Okada R; Ichikawa R; Omatsu T; Mizutani T; Katayama Y; Noguchi S; Iwai S; Nakagawa T; Shinohara Y; Kaneda M; Yamawaki H; Sasaki K
Cancer Sci; 2019 Sep; 110(9):2806-2821. PubMed ID: 31254429
[TBL] [Abstract][Full Text] [Related]
35. A one-stop microfluidic-based lung cancer organoid culture platform for testing drug sensitivity.
Jung DJ; Shin TH; Kim M; Sung CO; Jang SJ; Jeong GS
Lab Chip; 2019 Sep; 19(17):2854-2865. PubMed ID: 31367720
[TBL] [Abstract][Full Text] [Related]
36. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids.
Graham O; Rodriguez J; van Biljon L; Fashemi B; Graham E; Fuh K; Khabele D; Mullen M
J Vis Exp; 2023 Jan; (191):. PubMed ID: 36688549
[TBL] [Abstract][Full Text] [Related]
37. In vivo tumor growth of high-grade serous ovarian cancer cell lines.
Mitra AK; Davis DA; Tomar S; Roy L; Gurler H; Xie J; Lantvit DD; Cardenas H; Fang F; Liu Y; Loughran E; Yang J; Sharon Stack M; Emerson RE; Cowden Dahl KD; V Barbolina M; Nephew KP; Matei D; Burdette JE
Gynecol Oncol; 2015 Aug; 138(2):372-7. PubMed ID: 26050922
[TBL] [Abstract][Full Text] [Related]
38. A Three-Dimensional Organoid Culture Model to Assess the Influence of Chemicals on Morphogenetic Fusion.
Belair DG; Wolf CJ; Moorefield SD; Wood C; Becker C; Abbott BD
Toxicol Sci; 2018 Dec; 166(2):394-408. PubMed ID: 30496568
[TBL] [Abstract][Full Text] [Related]
39. Experimental models for ovarian cancer research.
Tsang SI; Hassan AA; To SKY; Wong AST
Exp Cell Res; 2022 Jul; 416(1):113150. PubMed ID: 35405118
[TBL] [Abstract][Full Text] [Related]
40. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
Saito Y; Muramatsu T; Kanai Y; Ojima H; Sukeda A; Hiraoka N; Arai E; Sugiyama Y; Matsuzaki J; Uchida R; Yoshikawa N; Furukawa R; Saito H
Cell Rep; 2019 Apr; 27(4):1265-1276.e4. PubMed ID: 31018139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
